Equities research analysts expect that Paratek Pharmaceuticals Inc (NASDAQ:PRTK) will announce ($1.17) earnings per share (EPS) for the current quarter, according to Zacks. Eight analysts have made estimates for Paratek Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.34) and the highest estimate coming in at ($1.05). Paratek Pharmaceuticals posted earnings per share of ($0.91) during the same quarter last year, which would indicate a negative year-over-year growth rate of 28.6%. The business is scheduled to issue its next earnings results on Wednesday, May 8th.
On average, analysts expect that Paratek Pharmaceuticals will report full year earnings of ($4.38) per share for the current year, with EPS estimates ranging from ($5.02) to ($3.58). For the next financial year, analysts expect that the firm will post earnings of ($3.10) per share, with EPS estimates ranging from ($4.55) to ($1.76). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Paratek Pharmaceuticals.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.06). The company had revenue of $17.02 million during the quarter, compared to analysts’ expectations of $16.50 million. Paratek Pharmaceuticals had a negative return on equity of 149.09% and a negative net margin of 656.41%.
A number of research firms have recently issued reports on PRTK. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, February 14th. HC Wainwright reissued a “buy” rating on shares of Paratek Pharmaceuticals in a research report on Thursday, February 28th. LADENBURG THALM/SH SH set a $18.00 price target on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, February 28th. Canaccord Genuity increased their price target on shares of Paratek Pharmaceuticals from $14.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, January 16th. Finally, Wedbush reissued an “outperform” rating on shares of Paratek Pharmaceuticals in a research report on Wednesday, March 6th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $23.25.
A number of large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its position in Paratek Pharmaceuticals by 1.4% in the fourth quarter. Bank of New York Mellon Corp now owns 138,282 shares of the specialty pharmaceutical company’s stock worth $710,000 after purchasing an additional 1,906 shares during the period. Annex Advisory Services LLC raised its stake in shares of Paratek Pharmaceuticals by 15.3% during the 4th quarter. Annex Advisory Services LLC now owns 15,100 shares of the specialty pharmaceutical company’s stock worth $77,000 after purchasing an additional 2,000 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Paratek Pharmaceuticals by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 308,773 shares of the specialty pharmaceutical company’s stock worth $1,584,000 after purchasing an additional 6,811 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Paratek Pharmaceuticals by 43.1% during the 4th quarter. Bank of America Corp DE now owns 23,504 shares of the specialty pharmaceutical company’s stock worth $120,000 after purchasing an additional 7,074 shares in the last quarter. Finally, Kalos Management Inc. raised its stake in shares of Paratek Pharmaceuticals by 81.8% during the 4th quarter. Kalos Management Inc. now owns 24,450 shares of the specialty pharmaceutical company’s stock worth $160,000 after purchasing an additional 11,000 shares in the last quarter. Hedge funds and other institutional investors own 74.30% of the company’s stock.
Shares of NASDAQ PRTK traded down $0.40 during mid-day trading on Wednesday, reaching $5.92. The company had a trading volume of 535,111 shares, compared to its average volume of 301,682. The company has a debt-to-equity ratio of 4.81, a current ratio of 14.41 and a quick ratio of 14.41. The firm has a market capitalization of $202.63 million, a price-to-earnings ratio of -1.66 and a beta of 1.52. Paratek Pharmaceuticals has a 12-month low of $4.50 and a 12-month high of $14.15.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Further Reading: Market Capitalization and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.